Introduction from CEO Frank Reynolds
TEDxBigApple – Robert Langer
Biomaterials for the 21st Century
“We’re Scientists and Engineers…we’re working to solve challenging problems.” – Robert S. Langer
Robert S Langer Founds Field of Drug Delivery Systems For Neuroscience
PixarBio’s co-founder Robert S. Langer, David H. Koch Institute Professor at MIT, has made key contributions to the field of neuroscience through the drug delivery inventions utilizing new biomaterials for neuroprotection, localized delivery of drugs, and for sustaining cell growth.
One example is the Gliadel Wafer, approved by the FDA in September 1996 and co-invented by Robert S. Langer, ScD, and Henry Brem, M.D., Chief of Neurosurgery at Johns Hopkins University. The dime-sized wafer delivers chemotherapy directly to a site of the brain a tumor removal. In 1996, The Gliadel Wafer became the first therapy in more than two decades to extend the lives of patients with a deadly brain cancer called glioblastoma. (1) NIH Gliadel Wafer.
Frank Reynolds Drives Biomaterials Use For The Spinal Cord Injury
In 2006, Frank Reynolds founded InVivo Therapeutics Corporation to advance biomaterials for spinal cord injury (SCI) from rats to human studies. Frank co-invented InVivo Therapeutics’ Neuroscaffold and its many iterations in the product development lifecycle. The US FDA approved human studies for the Neuroscaffold in 2013 with the first patient reporting no complications and some improved sensation. Patient enrollment is ongoing: www.clinicaltrials.com
PixarBio Drives Non-Opiate Drugs Delivery Systems for Neurological Conditions
PixarBio Corporation has developed a novel drug delivery platform to achieve sustained release of non-opiate drugs to treat post-operative, acute and chronic pain.
We believe over the next 5 years, we will create a new clinical franchise in medicine around our pain product pipeline. The biomaterials industry’s learning curves have shortened and time to market is faster as the industry evolves. As our drug delivery system for Parkinson’s disease, Epilepsy, and Spinal cord injury evolves, PixarBio will be ready to scale.
Neuroscience will remain the most unknown frontier in science and medicine where the opportunity for biomaterial interventions appears endless.